Dimensional Fund Advisors LP Lineage Cell Therapeutics, Inc. Transaction History
Dimensional Fund Advisors LP
- $403 Billion
- Q3 2024
A detailed history of Dimensional Fund Advisors LP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 40,449 shares of LCTX stock, worth $20,224. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,449
Previous 40,449
-0.0%
Holding current value
$20,224
Previous $40,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.2MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$20.8 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$4.78 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$4.3 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$2.5 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$2.5 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $84.9M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...